



Resonance Health Ltd
ASX / Media Release

6 March 2014

FerriScan Current Procedural Terminology (CPT) Code Update

Resonance Health Limited has received notification today that the request by a group of clinicians in the United States to develop a new Category 1 code to report MRI Post-Processing under concurrent supervision for measurement of liver iron concentration (LIC) has been rejected by the American Medical Association. The main rationale stated for the decision was that existing codes are adequate. The American College of Radiology (ACR) was also concerned that the request was vendor specific.

The ACR has suggested that a Healthcare Common Procedure Coding System (HCPCS) code for reimbursement of MRI post-processing for measurement of LIC may be more appropriate. The applicants for the new code have the opportunity to submit a formal request to the CPT Editorial Committee to reconsider its decision or progress alternative options such as an application for a HCPCS code for reimbursement.

Although this ruling is frustrating for the Company and for the considerable number of clinicians who strongly supported the need for this code, we are pleased that several payers in the US value the benefit of FerriScan in the management of their patients and are currently reimbursing the cost of the FerriScan service for claims that utilize the existing CPT codes. The Company will continue to work with clinicians and insurance payers to gain further medical insurance coverage for FerriScan via these codes in the US.

The number of FerriScans provided to the US market grew by 33% in the last financial year compared to the previous year and demand continues to grow in the US where FerriScan is the only FDA approved product for the measurement of liver iron concentration. The US market currently represents approximately 20% of the Company's FerriScan income. Recent growth in FerriScan volumes has been driven by Middle East and Asian countries where the Company has received sizable orders in recent months.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300

E: lizad@resonancehealth.com

Adrian Bowers
Company Secretary
T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.